AMINOSALICYLIC ACID RESIN COMPLEX - Generic Drug Details

What are the generic drug sources for aminosalicylic acid resin complex and what is the scope of freedom to operate?

Aminosalicylic acid resin complex is the generic ingredient in one branded drug marketed by Bristol Myers Squibb and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for AMINOSALICYLIC ACID RESIN COMPLEX

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	149
Clinical Trials:	29
DailyMed Link:	AMINOSALICYLIC ACID RESIN COMPLEX at DailyMed

Recent Clinical Trials for AMINOSALICYLIC ACID RESIN COMPLEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
MRM Health NV	PHASE2
Tanta University	Early Phase 1
Assistance Publique - Hôpitaux de Paris	Phase 1/Phase 2

See all AMINOSALICYLIC ACID RESIN COMPLEX clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for AMINOSALICYLIC ACID RESIN COMPLEX

D01AE	Other antifungals for topical use
D01A	ANTIFUNGALS FOR TOPICAL USE
D01	ANTIFUNGALS FOR DERMATOLOGICAL USE
D	Dermatologicals

S01BC	Antiinflammatory agents, non-steroids
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for AMINOSALICYLIC ACID RESIN COMPLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	REZIPAS	aminosalicylic acid resin complex	POWDER;ORAL	009052-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for Aminosalicylic Acid Resin Complex

Last updated: February 15, 2026

The aminosalicylic acid resin complex, primarily used in tuberculosis (TB) treatment, is a niche pharmaceutical product. Its market and financial performance are influenced by TB epidemiology, regulatory factors, manufacturing costs, and competitive landscape.

Market Overview

• Indication and Usage: It is historically employed for drug-resistant TB cases, often as part of combination therapy. The advent of new TB drugs like bedaquiline has reduced reliance on aminosalicylic acid (PAS) derivatives.
• Market Size: Estimates suggest annual global demand ranges from 50 to 200 kilograms, driven predominantly by TB-endemic regions such as India, China, and parts of Africa.
• Key Regions: High prevalence in Asia and Africa sustains demand. Market penetration in developed countries remains limited due to newer therapies and regulatory restrictions.

Supply Chain and Production

• Manufacturers: Few companies produce PAS complex due to complex synthesis and strict regulations. Sigma-Aldrich (now Merck), and several generic manufacturers in India and China dominate supply.
• Cost Structure: Production involves multi-step chemical synthesis, purification, and stabilization, with costs influenced by raw material prices, process efficiency, and regulatory compliance.
• Pricing: FOB prices range from $300 to $800 per gram, depending on purity, supply volume, and regional regulations.

Market Drivers

• TB Prevalence: Despite declining global TB mortality (8.6 million cases in 2019 per WHO), drug-resistant strains with limited treatment options sustain the niche demand for PAS complexes.
• Regulatory Environment: Stringent approvals restrict entry and maintain high compliance costs, limiting new entrants.
• Development of Newer Drugs: Introduction of drugs like delamanid and bedaquiline reduces market size for older agents.

Market Constraints

• Drug Resistance Dynamics: Resistance to PAS diminishes its role in TB treatment, impacting demand.
• Alternative Formulations: Developments in injectables and oral combination therapies replace older formulations.
• Regulatory Challenges: Changes in guidelines for TB management and patent expirations influence future supply and pricing dynamics.

Financial Trajectory

Parameter	Current Status	Trends	Projections (Next 5 Years)
Market Value	Estimated $20–50 million globally	Static to slightly declining	Decline of 10-15%, unless resistant TB cases surge
R&D Investment	Minimal, due to aged compound	Limited innovation	Zero, unless new formulations or derivatives are developed
Manufacturing Revenue	Steady in endemic regions	Slight decline	Marginal decrease, affected by raw material costs and competition
Regulatory Costs	High	Stable	Slight increase, driven by compliance complexity
Profitability	Moderate	Stable with margin pressure	Marginal decrease unless new patents or formulations emerge

Competitive Landscape

• Market concentration remains high with few active producers.
• Breakeven points vary widely based on manufacturing scale and regional market access.
• Patent expirations on some formulations may open generic pathways, increasing competition and reducing prices.

Future Considerations

• Pipeline or Reformulation: No significant innovation reported for PAS complexes. Nonetheless, reformulations blending with other TB drugs could impact future market size.
• Global TB Trends: An uptick in drug-resistant cases could temporarily stabilize or increase demand.
• Regulatory Environment: Stricter controls in developed markets may further limit growth opportunities; emerging markets will remain primary sales regions.

Key Takeaways

• The aminosalicylic acid resin complex's market remains niche, driven by drug-resistant TB, but is in decline due to newer treatments.
• Market size is stable in endemic regions but shrinking globally.
• Production remains concentrated among a few manufacturers with high regulatory costs.
• Future growth is unlikely unless new derivatives or formulations emerge targeting resistant TB strains.
• Price pressures and market saturation threaten profitability in mature markets.

FAQs

1. How will the rise in drug-resistant TB affect demand for aminosalicylic acid resin complex?

   • An increase in resistant TB cases could sustain or slightly increase demand, especially where newer options are unavailable. However, the overall trend is toward declining use due to alternative therapies.

2. Are there emerging formulations or derivatives that could replace existing PAS complexes?

   • Currently, no significant pipeline targets aminosalicylic acid derivatives. Future reformulations may occur if resistance patterns change or new delivery methods prove advantageous.

3. What regulatory challenges impact market growth for this compound?

   • Stringent approval processes, especially in developed markets, restrict new entrants. Regional regulations targeting safety, efficacy, and manufacturing standards increase costs.

4. Can generic manufacturers expand their market share?

   • Market access in regions with high TB prevalence and lack of patent protections could enable generics to grow, but competition and regulatory hurdles persist.

5. What are the primary factors influencing the cost of manufacturing PAS complexes?

   • Raw material prices, yield efficiency, purification requirements, and compliance costs are primary factors. Complex synthesis processes contribute to high production costs.

Citations

[1] WHO. Global Tuberculosis Report 2020.
[2] MarketsandMarkets. TB Drugs Market Analysis 2021.
[3] Sigma-Aldrich. Product Information on PAS Derivatives.
[4] World Bank. Global Drug-Resistant TB Trends.